Dr Channa Debruyne

PDC*line Pharma welcomes Dr Channa Debruyne

PDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.

An expert in clinical and scientific research into chemotherapeutic products and cancer vaccines, Dr Channa Debruyne will take over the management of the ongoing trial in non-small-cell lung cancer (NSCLC).
“We are very pleased to welcome Dr Channa Debruyne, who will play a key role in the development of PDC*line Pharma’s clinical plan. She has the experience and expertise we are looking for to strengthen our management team,” said Eric Halioua, president & CEO at PDC*line Pharma. “With more than 25 years international experience in clinical and scientific research in chemotherapeutic products and cancer vaccines, she will lead the ongoing phase I/II trial with our cancer vaccine candidate (PDC*lung01) for NSCLC.”
Dr Channa Debruyne said: “It is with great pleasure that I join PDC*line Pharma. I look forward to working in close collaboration with the PDC*line Pharma management team to bring this cancer vaccine with a breakthrough technology to patients.”